CD8A and myeloid sarcoma: A deterioration in MS symptoms and/or neurological examination findings between the 6-month and the 2-year assessments was observed in 6 participants (participants 1, 2, 6, 8, 9, and 12), of whom 4 (participants 1, 2, 6, and 8) received T cell therapy with weak EBV reactivity (<5% of CD8+ T cells reacting to EBV) (Table 2).